Ja silmatüüpidel on ARVO.<br /><br />sB
arvol see aasta ka eesti firma kohal. asper biotech oma silmaharuga www.asperophthalmics.com <br /><br />
EYET puhul kardetakse enim DNA uut ravimit Lucentis, mille katsetustulemused peaks tulema 2Q-3Q. Otsene konkurent EYETi Macugenile. Mõned usuvad, et EYET võib selle peale liikuda <br />-20% - +60%.
DNDN esmaspäeval suure tõenäosusega rallimas<br /><br />Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival in Advanced... [FCQPQGY]<br />Dendreon D9901 Phase 3 Data Showing Provenge Significantly Improves Survival<br />in Advanced Prostate Cancer Patients Presented at ASCO<br /><br />ORLANDO, Fla., May 14 /PRNewswire-FirstCall/ -- Dendreon Corporation<br />(Nasdaq: DNDN) announced today that, as previously reported at the ASCO<br />Prostate Cancer Symposium in February, Provenge(R), the Company's<br />investigational immunotherapy for the treatment of prostate cancer,<br />significantly improved survival in men with asymptomatic, metastatic<br />androgen-independent (hormone-refractory) prostate cancer when compared to<br />patients receiving placebo. The study was presented today at the 2005<br />American Society of Clinical Oncology (ASCO) Annual Meeting by Eric J. Small,<br />M.D., professor of medicine and urology at the University of California, San<br />Francisco.<br />Dr. Small presented the final three-year intent-to-treat analysis of the<br />Company's first randomized Phase 3 clinical study, known as Study D9901. In<br />Study D9901, patients receiving Provenge had a median survival of 25.9 months<br />compared to 21.4 months for patients in the placebo arm, a 4.5 month<br />improvement (p-value = 0.01, hazard ratio = 1.7). This hazard ratio implies<br />that patients receiving placebo have a relative risk of dying that is<br />70 percent higher than those patients receiving Provenge. In addition,<br />34 percent of patients receiving Provenge were alive at 36 months compared to<br />11 percent of patients receiving placebo (p-value = 0.0046). Provenge was<br />well tolerated with the most common adverse events reported being fever and<br />chills lasting for one to two days.<br /> For the first time, Dr. Small also presented new data from an analysis of<br />subsequent therapy that men received after their disease had progressed.<br />Pursuant to the D9901 study protocol, at the time patients in the study<br />developed objective disease progression, they were then treated at their<br />physician's discretion, including the use of chemotherapy. The results of<br />this additional analysis showed that there were no imbalances between the two<br />treatment arms of the trial with regard to the subsequent use of chemotherapy.<br />This was true for both docetaxel (Taxotere(R))-based regimens, as well as<br />other chemotherapy-based regimens. In addition, Dr. Small presented new data<br />from a commonly performed statistical analysis, known as a Cox regression<br />multivariate analysis, to further test the validity of the survival benefit<br />seen in this study. The results of this analysis confirm that the survival<br />benefit observed in this study was not due to any imbalances in the patient<br />population.<br /> "These important additional analyses give us more confidence in the<br />survival outcome we observed in this trial and further underscore the<br />potential utility Provenge may have in this patient population for which few<br />appealing treatment options exist," said Dr. Small. "A targeted agent with<br />this type of survival benefit, combined with a favorable safety profile, has<br />the potential to provide an important new treatment option for prostate cancer<br />patients."<br /> Study Details<br /> The D9901 study was a double-blind, placebo-controlled Phase 3 trial<br />evaluating Provenge in men with asymptomatic, metastatic androgen independent<br />prostate cancer. The study was designed to measure time to disease<br />progression and time to development of disease-related pain in men with<br />androgen independent prostate cancer. In addition, a 36 month final survival<br />analysis was required per the study design. The study was conducted at 19<br />institutions in the United States and enrolled 127 men to receive three<br />infusions of Provenge or placebo over a four-week period.
DNDN-l üle 13 milli aktsia lühikeseks müüdud. Valus saab see neile homme olema.
"...As previously reported at the ASCO Prostate Cancer Symposium in February.."<br /><br />Üht-teist huvitavat siiski oli. Kirjutan veidi aja pärast Pro all lähemalt.<br /><br />sB<br />
Et nüüd tahetakse kombineerida kaks miinust kokku üheks plussiks :)<br /><br />NEW YORK, Aug 21 (Reuters) - OSI Pharmaceuticals <OSIP.O> <br />said on Sunday it agreed to buy eye disease treatment maker <br />Eyetech Pharmaceuticals Inc. <EYET.O> for around $935 million in <br />cash and stock. <br /> OSI will buy all outstanding Eyetech common shares for $20 <br />each, the companies said -- a 43 percent premium to Eyetech's <br />Aug. 19 closing price of $13.99. <br /> The agreement calls for 75 percent of the purchase price, or <br />$15 per share, to be paid in cash with the rest to be paid in <br />OSI common stock using an exchange ratio of 0.12275 OSI shares <br />for each Eyetech share.